|
|
 |
|
Viewing report
|
|
|
|
Neuropathic Pain: Competing Treatments and Market Entry Considerations
BioPharm Reports (VennBio Ltd.), June 2010, Pages: 195
This report presents the findings of a global study of current therapeutic approaches to the treatment of Neuropathic Pain (NP). These findings were made following the participation of more than 330 clinics, who provided details of their treatments and prescribing practices. This was carried out as part of a competitor insight and market entry study, in the neuropathic pain field.
With estimated prevalence levels of 3-10%, the treatment of Neuropathic Pain (NP) remains an area of significant unmet need. NP is highly individual in its presentation, level, underlying pathology and response to therapy. For some patients, available therapies give satisfactory pain control. For many others, treatments are poor or do not work at all. Therapeutic options include more than ten drug classes, which are commonly prescribed in combinations tailored to individual patient needs.
Overview:
- Comprehensive details of current treatments for NP, provided by more than 330 clinics in 56 countries
- In-depth information relevant to markets and opportunities in the NP field
- 98% of participants are practicing physicians, working in specialised areas of pain treatment. Of these, 78% described themselves as specialists in pain treatment
- Leading participant countries were USA, Canada, UK, Australia, Denmark, France, Brazil, Germany, Netherlands and Belgium
- 74% of the clinical centres participating in this study were hospital pain departments, specialised pain practices or private pain clinics. Detailed information on the use of specific drug classes including tricyclic antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers, opioids, NSAIDS, cannabinoids and Capsaicin
- Physicians have provided detailed feedback on the underlying pathologies associated with NP, seen in their patients
- Comprehensive information on the most frequently prescribed drugs from nine drugs classes, including drug combinations, for the treatment of NP. Biopharm Reports believes this provides the most comprehensive and up-to-date review and analysis in this area, currently available
- A detailed analysis of interventional methods used for the treatment of NP (e.g. peripheral nerve block, TENS)
- An assessment of average levels of pain relief achieved in the treatment of NP, in relation to 12 underlying conditions
- Informative views of participating physicians on current limitations, challenges and issues relating to the treatment of NP
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
Neuropathic Pain: Emerging Drugs and Current Treatment Practices
Neuropathic Pain: A Global Survey of Treatment Practices
Pain Therapeutics - Drugs, Markets and Companies
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
Peripheral Neuropathy and Neuropathic Pain 2008
US Cancer Pain Report
Can a New Antidepressant Establish Itself in a Highly Competitive Market?
Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
US Neuropathic Pain 2008 - 4th Edition: Market Potential Through 2018
|
|
|
|
